An activated JAK/STAT3 pathway and CD45 expression are associated with sensitivity to Hsp90 inhibitors in multiple

Huiqiong Lin1, Iryna Kolosenko, Ann-Charlotte Björklund

  • 1Department of Oncology-Pathology, Cancer Centre Karolinska, Karolinska Institutet, Stockholm, Sweden.

Experimental Cell Research
|December 19, 2012
PubMed

Insights

Hsp90 inhibitors like 17DMAG show differential activity in multiple myeloma (MM). CD45(+) MM cells with activated JAK/STAT3 pathways are sensitive, while CD45(-) cells with PI3K pathway activation are resistant.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • Heat shock protein 90 (Hsp90) is crucial for signaling protein activity, including JAK/STAT and PI3K pathways.
  • Hsp90 inhibitors (Hsp90-Is) have shown variable efficacy in multiple myeloma (MM) clinical trials.

Purpose of the Study:

  • To investigate the signaling pathways responsible for differential sensitivity to the Hsp90 inhibitor 17DMAG in MM cell lines and primary cells.
  • To identify biomarkers predicting response to Hsp90 inhibition in MM.

Main Methods:

  • Treatment of MM cell lines and primary MM cells with 17DMAG.
  • Analysis of JAK/STAT3 and PI3K pathway activation.
  • Assessment of CD45 expression levels.
  • Evaluation of apoptosis and caspase-3 activation.
  • Over-expression of STAT3C and Mcl-1 to assess their role in drug resistance.

Main Results:

  • CD45(+) MM cell lines with activated JAK/STAT3 were sensitive to 17DMAG, undergoing apoptosis.
  • CD45(-) MM cell lines dependent on PI3K signaling were more resistant.
  • IL-6 treatment induced CD45 and pSTAT3, sensitizing resistant cells to 17DMAG.
  • Primary MM cells with high CD45 expression showed higher pSTAT3 and increased caspase-3 activation upon 17DMAG treatment.
  • STAT3 inhibition was key to Hsp90-Is' pro-apoptotic effects, while STAT3C over-expression conferred resistance.
  • Mcl-1 down-regulation by 17DMAG was attenuated in STAT3C-expressing cells.

Conclusions:

  • CD45 expression and JAK/STAT3 pathway activation are key determinants of sensitivity to Hsp90 inhibitors in MM.
  • Hsp90 inhibition targets the JAK/STAT3 pathway, leading to apoptosis in sensitive MM cells.
  • High CD45 expression identifies MM patients likely to benefit from Hsp90-I therapy.

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...